Cyclacel pulls the plug on Daiichi-partnered chemo — 8 years after a failed PhIII in AML

2022-11-10

临床3期引进/卖出临床结果临床终止

Hovering around penny stock territory, New Jersey-based Cyclacel Pharmaceuticals $CYCC said yesterday it’s finally going to call it quits on a Daiichi Sankyo-partnered cancer drug candidate that saw a Phase III flop in acute myeloid leukemia in late 2014.

First licensed from Daiichi back in 2003, Cyclacel says it now wants to terminate the development of sapacitabine, and its license agreement with Daiichi on the drug “for commercial reasons,” with the termination effective by March 23, 2023.

Back in late 2014, a data and safety monitoring board called to halt that sapacitabine study in AML due to futility, but the company continued the trial into 2017, ultimately finding that it did not show an overall survival benefit. The median OS was 5.9 months on the study arm versus 5.7 months on the control arm (P = .8902), according to the results published last year.

The drug was also tested in mid-stage trials for other cancers like myelodysplastic syndromes and lung cancer.

Cyclacel unveils a flop in leukemia 2 years after a call on futility, but still won’t give up

Meanwhile, Cyclacel said in its earnings report yesterday that it’s also working on an ongoing Phase I/II study of oral fadraciclib in solid tumors and lymphoma, and its cash runway has been extended through the end of next year.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构